Want to see AU:VIT full AI Analyst Report?
VIT Stock Chart & Stats
AU$0.06
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.06
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.08
Previous CloseN/A
Volume1.00K
Average Volume (3M)228.84K
Market Cap
AU$18.56M
Enterprise ValueAU$31.12M
Total Cash (Recent Filing)AU$6.10M
Total Debt (Recent Filing)AU$17.34M
Price to Earnings (P/E)25.8
Beta1.65
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.28%
Share Statistics
EPS (TTM)<0.01
Shares Outstanding662,741,800
10 Day Avg. Volume238,134
30 Day Avg. Volume228,844
Financial Highlights & Ratios
PEG Ratio-1.00
Price to Book (P/B)0.78
Price to Sales (P/S)0.30
P/FCF Ratio14.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Capital StructureA low debt-to-equity ratio (0.25) and a strong equity ratio (63.85%) provide durable financial flexibility. This conservative leverage profile reduces interest burden, preserves borrowing capacity for strategic investment or working capital, and helps the company withstand regulatory and demand volatility common in the medicinal cannabis sector.
Stable Gross MarginA roughly 27% gross margin indicates the business retains a meaningful portion of sales after direct costs. Durable gross-margin stability reflects consistent product economics and cost control, supporting long-term gross cash generation and providing a buffer to fund SG&A or product development as revenues fluctuate.
High FCF-to-net-income ConversionA near-1.0 free cash flow to net income ratio shows the company historically converts reported earnings into free cash flow when profitable. This structural ability to turn accounting profits into discretionary cash supports investment, deleveraging or shareholder returns once revenue trends stabilize.
Bears Say
Severe Free Cash Flow DeclineAn extreme FCF collapse (>-2000%) is a persistent risk to operations and strategic flexibility. Such a structural drop can force reliance on external financing, constrain capital expenditure and product rollouts, and increase vulnerability to funding shocks in a capital-intensive, regulated industry.
Poor Operating Cash ConversionOperating cash flow delivers only ~14% of reported net income, signaling weak cash conversion from core operations. Over months, this gap can reflect working-capital drain or non-cash earnings, undermining the company's ability to self-fund growth, service commitments, or sustain distributions without external capital.
Low Profitability MarginsModest net margin (~2.7%) and low operating margins indicate limited efficiency and little headroom to absorb cost inflation or competitive price pressure. Structurally low margins reduce retained earnings for reinvestment and make it harder to scale profitably in a competitive specialty pharmaceutical and cannabis market.
Cronos Australia Ltd. News
VIT FAQ
What was Cronos Australia Ltd.’s price range in the past 12 months?
Cronos Australia Ltd. lowest share price was AU$0.02 and its highest was AU$0.07 in the past 12 months.
What is Cronos Australia Ltd.’s market cap?
Cronos Australia Ltd.’s market cap is AU$18.56M.
When is Cronos Australia Ltd.’s upcoming earnings report date?
Cronos Australia Ltd.’s upcoming earnings report date is Aug 26, 2026 which is in 41 days.
How were Cronos Australia Ltd.’s earnings last quarter?
Cronos Australia Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Cronos Australia Ltd. overvalued?
According to Wall Street analysts Cronos Australia Ltd.’s price is currently Overvalued.
Does Cronos Australia Ltd. pay dividends?
Cronos Australia Ltd. pays a Annually dividend of AU$0.002 which represents an annual dividend yield of 3.28%. See more information on Cronos Australia Ltd. dividends here
What is Cronos Australia Ltd.’s EPS estimate?
Cronos Australia Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cronos Australia Ltd. have?
Cronos Australia Ltd. has 662,741,800 shares outstanding.
What happened to Cronos Australia Ltd.’s price movement after its last earnings report?
Cronos Australia Ltd. reported an EPS of -AU$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.167%.
Which hedge fund is a major shareholder of Cronos Australia Ltd.?
Currently, no hedge funds are holding shares in AU:VIT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cronos Australia Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.51%
12-Months-Change
Fundamentals
Return on Equity
1.66%
Trailing 12-Months
Asset Growth
8.56%
Trailing 12-Months
Company Description
Cronos Australia Ltd.
Established in 2018 and based in South Yarra, Australia, Vitura Health Limited focuses on the supply and marketing of medicinal cannabis goods throughout Australia and the Asian market. The company manages a portfolio of key brands, such as CanView, Burleigh Heads Cannabis, CDA Clinics, Cannadoc, and Adaya. This entity was formerly recognized as Cronos Australia Limited before adopting the name Vitura Health Limited in February 2023.
Technical Analysis
Elixinol Wellness
―
Cann Group
―
Vita Life Sciences Limited
―
Little Green Pharma Ltd.
―
Althea Group Holdings Ltd.
―